Advanced wound care business Crawford Healthcare has signed a transatlantic deal as it prepares to launch a new dressing in the world’s biggest wound care market.
The Cheshire-headquartered firm put pen to paper on a three-year national group purchasing agreement in the US with Premier Inc., which supports an alliance of 3,750 hospitals and over 130k healthcare providers.
Crawford originally announced a 12-month deal with Premier Inc. last April, but the company has now joined the full three-year approval cycle in an agreement expected to boost sales for its expanding US subsidiary, Crawford Healthcare Inc.
Chris Lane, the firm’s director of strategy, said: "The US continues to play a major part in our international growth strategy, with sales currently doubling year-on-year as the market becomes more aware of the significance of our products.
"Over the past 12 months, we’ve established a great relationship with Premier Inc’s extensive network of hospitals and we’re confident that clinical support for our products will only grow with the security of a full three-year agreement behind us."
The agreement was signed ahead of the launch of Kerracel Ag exclusively in the US.
Crawford said the product boasts an "unrivalled ability” to kill bacteria within a biofilm.
Richard Anderson, the CEO of Crawford Healthcare, commented: "Independent data produced by the University of Manchester suggests that we will very shortly be marketing the most clinically effective advanced wound dressing available in North America.
"The success of our US subsidiary to date has been fantastic but, with this new product in mind, remains only the tip of what we’re hoping to achieve internationally as we continue to contend with global health issues including an ageing and increasingly diabetic population."